Vimarsana
Biggest News Aggregation in the World

Page 20 - Gene Expression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gene Expression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gene Expression Today - Breaking & Trending Today

Mic60-low gene signature may be a simple tool to estimate pancreatic cancer risk - Vimarsana News

Mic60-low gene signature may be a simple tool to estimate pancreatic cancer risk

The mitochondria is a key energy-producing component of the human cell that plays an important role in cancer cell metabolism.

Unlocking more information from liquid biopsies - Vimarsana News

Unlocking more information from liquid biopsies

Fred Hutch computational biologist Dr. Gavin Ha received an NIH New Innovator Award to develop new assays and computational methods that will allow him to mine cancer patient blood samples for new information that can improve diagnosis, treatment and disease monitoring.

Research discovers cancer causing-gene controlling variations in prostate cancer - Vimarsana News

Research discovers cancer causing-gene controlling variations in prostate cancer

Research published in the journal Cell Report, by several reputed institutes, finds how cancer-causing gene regulate genetic variation in prostate cancer

Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions - Vimarsana News

Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions

Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions - read this article along with other careers information, tips and advice on BioSpace

Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy - Vimarsana News

Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

The EC approval is based on positive 18-month results from the HELIOS-A Phase 3 study, where AMVUTTRA significantly improved the signs and symptoms of hATTR amyloidosis, with more than 50 percent of patients experiencing halting or reversal of their polyneuropathy manifestations.